

Chao Shen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10051088/publications.pdf>

Version: 2024-02-01

23
papers

2,682
citations

516710

16
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

3663
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA N6-methyldeoxyadenosine in mammals and human disease. Trends in Genetics, 2022, 38, 454-467.	6.7	23
2	Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2. Cell Reports, 2022, 38, 110253.	6.4	6
3	METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis. Nature Cell Biology, 2022, 24, 205-216.	10.3	143
4	R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. Molecular Cell, 2021, 81, 922-939.e9.	9.7	157
5	Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica, 2020, 105, 148-160.	3.5	41
6	RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. Cell Stem Cell, 2020, 27, 64-80.e9.	11.1	225
7	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell, 2020, 38, 79-96.e11.	16.8	389
8	Consistency analysis of microRNA arm expression reveals microRNA-369-5p/3p as tumor suppressors in gastric cancer. Molecular Oncology, 2019, 13, 1605-1620.	4.6	18
9	Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. Nature, 2019, 567, 414-419.	27.8	452
10	Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance. Blood, 2019, 134, 233-233.	1.4	5
11	TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8. Blood, 2019, 134, 1249-1249.	1.4	0
12	METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell, 2018, 22, 191-205.e9.	11.1	749
13	N6-Methyladenosine Modification Regulates Cell Metabolism in Acute Myeloid Leukemia. Blood, 2018, 132, 880-880.	1.4	0
14	ALKBH5 Functions As an Oncogene in Acute Myeloid Leukemia. Blood, 2018, 132, 3910-3910.	1.4	0
15	Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nature Communications, 2017, 8, 2099.	12.8	45
16	microRNA-451-modulated hnRNP A1 takes a part in granulocytic differentiation regulation and acute myeloid leukemia. Oncotarget, 2017, 8, 55453-55466.	1.8	12
17	Targeted Inhibition of STAT/TET1 Axis As a Potent Therapeutic Strategy for Acute Myeloid Leukemia. Blood, 2017, 130, 857-857.	1.4	1
18	The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia. PLoS Genetics, 2016, 12, e1006259.	3.5	51

#	ARTICLE	IF	CITATIONS
19	c-Myc suppresses miR-451-3p/WTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 77430-77443.	1.8	29
20	ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6. <i>Scientific Reports</i> , 2015, 5, 16229.	3.3	53
21	PU.1-Regulated Long Noncoding RNA Inc-MC Controls Human Monocyte/Macrophage Differentiation through Interaction with MicroRNA 199a-5p. <i>Molecular and Cellular Biology</i> , 2015, 35, 3212-3224.	2.3	90
22	miR-199a-5p inhibits monocyte/macrophage differentiation by targeting the activin A type 1B receptor gene and finally reducing C/EBP β expression. <i>Journal of Leukocyte Biology</i> , 2014, 96, 1023-1035.	3.3	34
23	MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. <i>Blood</i> , 2012, 119, 4992-5004.	1.4	158